Eculizumab as rescue therapy for antibody-mediated rejection in a high-risk lung transplant recipient: A case report
Eculizumab may represent a viable rescue option in cases of refractory AMR after lung transplantation, including in patients requiring ECMO support. This case highlights the importance of tailored therapeutic strategies and multidisciplinary evaluation in managing high-risk transplant recipients.
Authors
- Jordi Riera (ORCID: https://orcid.org/0000-0002-1738-4448)
- Laura Doménech Moral (ORCID: https://orcid.org/0000-0002-7408-314X)
- Alba Pau‐Parra (ORCID: https://orcid.org/0000-0001-9773-8690)
- Cristina Berastegui (ORCID: https://orcid.org/0000-0001-9774-9349)
- Adrián Puertas Sanjuán (ORCID: https://orcid.org/0000-0001-8905-3501)
- María Rosa Gómez Domingo
- Irina B. Torres (ORCID: https://orcid.org/0000-0003-3304-0810)
- Pilar Lalueza Broto
- Joel Rosado Rodriguez
- Judit Sacanell-Lacasa
Institutions
- Hebron University (PS)
- Vall d'Hebron Hospital Universitari (ES)
Publication Details
- Journal
- American Journal of Health-System Pharmacy
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1093/ajhp/zxaf298
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00